Medpace Holdings (MEDP) Tops Q2 EPS by 8c, Beats on Revenues; Offers FY17 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Medpace (MEDP) PT Raised to $31 at Jefferies; Remains Sidelined
August 2, 2017 8:59 AM EDTJefferies raised its price target on Medpace (NASDAQ: MEDP) to $31.00 (from $30.00) while maintaining a Hold rating. Bad debt was reduced/avoided, and bookings improved sequentially. EBITDA guidance post 1Q17 ($106-108M) included $2-3M of bad debt exposure expected to hit the... More
